Antibacterial Therapy in Adults with COVID-19
Since the emergence of the Coronavirus-19 infectious disease (COVID-19) pandemic, a rising number of reports have underlined the risk of increasing antimicrobial resistance due to antibiotic overuse in COVID-19 patients. In addition, many physicians and pharmacists involved in antimicrobial stewards...
Saved in:
| Format: | Online |
|---|---|
| Language: | English |
| Published: |
MDPI - Multidisciplinary Digital Publishing Institute
2023
|
| Subjects: | |
| Online Access: | ONIX_20230405_9783036568133_80 |
| Tags: |
No Tags, Be the first to tag this record!
|
| _version_ | 1869525834550738944 |
|---|---|
| collection | Directory of Open Access Books |
| description | Since the emergence of the Coronavirus-19 infectious disease (COVID-19) pandemic, a rising number of reports have underlined the risk of increasing antimicrobial resistance due to antibiotic overuse in COVID-19 patients. In addition, many physicians and pharmacists involved in antimicrobial stewardship have had to shift their activities to the containment of the COVID-19 crisis. In contrast to this observed overconsumption of antibiotics, very few bacterial superinfections have been documented in COVID-19 patients, especially in patients admitted outside the intensive care unit and in the first days of admission. However, the identification of bacterial co-/superinfections in COVID-19 patients is difficult, as inflammatory and radiological markers of bacterial infection lack specificity in this setting. Furthermore, studies regarding the effect of immune suppression, including the use of corticosteroids and anti-interleukins, and the effect of potential immunomodulatory properties of certain antibiotics on the occurrence of bacterial co-/superinfection are needed.This Special Issue of Antibiotics aims to increase our knowledge regarding (more or less specific) markers associated with bacterial co-/superinfection in COVID-19 patients, quantitative and qualitative data regarding antibiotic prescriptions in COVID-19 patients, potential beneficial effects of antibiotic use in certain COVID-19 subgroups, detrimental effects associated with antibiotic overuse in COVID-19 patients, and evidence-based guidelines, which could facilitate the decision-making process when antibiotic prescriptions are considered. |
| format | Online |
| id | doab-20.500.12854ir-98801 |
| institution | Directory of Open Access Books |
| language | eng |
| publishDate | 2023 |
| publishDateRange | 2023 |
| publishDateSort | 2023 |
| publisher | MDPI - Multidisciplinary Digital Publishing Institute |
| publisherStr | MDPI - Multidisciplinary Digital Publishing Institute |
| record_format | ojs |
| spelling | doab-20.500.12854ir-988012024-03-31T13:10:35Z Antibacterial Therapy in Adults with COVID-19 Allard, Sabine Danielle Van Laethem, Johan COVID-19 antimicrobial use multicentre point-prevalence study Influenza co-infection secondary infections aspergillosis ivermectin randomized-controlled trial prevention treatment SARS-CoV-2 antiviral antibiotic azithromycin remdesivir macrolides virus coronavirus immunolides antivirus pandemics procalcitonin SARS virus community-acquired infections emergency service hospital pneumonia viral community-acquired pneumonia Mid-regional Pro-adrenomedullin ARDS biomarker prognosis superinfection bacterial co-infection bacterial superinfection antibiotic stewardship AMR antibiotics cephalosporin secondary infection variant of concern interleukin-6 receptor antagonist early administration mortality rates thema EDItEUR::M Medicine and Nursing thema EDItEUR::M Medicine and Nursing::MJ Clinical and internal medicine Since the emergence of the Coronavirus-19 infectious disease (COVID-19) pandemic, a rising number of reports have underlined the risk of increasing antimicrobial resistance due to antibiotic overuse in COVID-19 patients. In addition, many physicians and pharmacists involved in antimicrobial stewardship have had to shift their activities to the containment of the COVID-19 crisis. In contrast to this observed overconsumption of antibiotics, very few bacterial superinfections have been documented in COVID-19 patients, especially in patients admitted outside the intensive care unit and in the first days of admission. However, the identification of bacterial co-/superinfections in COVID-19 patients is difficult, as inflammatory and radiological markers of bacterial infection lack specificity in this setting. Furthermore, studies regarding the effect of immune suppression, including the use of corticosteroids and anti-interleukins, and the effect of potential immunomodulatory properties of certain antibiotics on the occurrence of bacterial co-/superinfection are needed.This Special Issue of Antibiotics aims to increase our knowledge regarding (more or less specific) markers associated with bacterial co-/superinfection in COVID-19 patients, quantitative and qualitative data regarding antibiotic prescriptions in COVID-19 patients, potential beneficial effects of antibiotic use in certain COVID-19 subgroups, detrimental effects associated with antibiotic overuse in COVID-19 patients, and evidence-based guidelines, which could facilitate the decision-making process when antibiotic prescriptions are considered. 2023-04-05T12:51:49Z 2023-04-05T12:51:49Z 2023 book ONIX_20230405_9783036568133_80 9783036568133 9783036568126 https://directory.doabooks.org/handle/20.500.12854/98801 eng application/octet-stream Attribution 4.0 International https://mdpi.com/books/pdfview/book/6837 https://mdpi.com/books/pdfview/book/6837 MDPI - Multidisciplinary Digital Publishing Institute 10.3390/books978-3-0365-6812-6 10.3390/books978-3-0365-6812-6 46cabcaa-dd94-4bfe-87b4-55023c1b36d0 9783036568133 9783036568126 132 Basel open access |
| spellingShingle | COVID-19 antimicrobial use multicentre point-prevalence study Influenza co-infection secondary infections aspergillosis ivermectin randomized-controlled trial prevention treatment SARS-CoV-2 antiviral antibiotic azithromycin remdesivir macrolides virus coronavirus immunolides antivirus pandemics procalcitonin SARS virus community-acquired infections emergency service hospital pneumonia viral community-acquired pneumonia Mid-regional Pro-adrenomedullin ARDS biomarker prognosis superinfection bacterial co-infection bacterial superinfection antibiotic stewardship AMR antibiotics cephalosporin secondary infection variant of concern interleukin-6 receptor antagonist early administration mortality rates thema EDItEUR::M Medicine and Nursing thema EDItEUR::M Medicine and Nursing::MJ Clinical and internal medicine Antibacterial Therapy in Adults with COVID-19 |
| title | Antibacterial Therapy in Adults with COVID-19 |
| title_full | Antibacterial Therapy in Adults with COVID-19 |
| title_fullStr | Antibacterial Therapy in Adults with COVID-19 |
| title_full_unstemmed | Antibacterial Therapy in Adults with COVID-19 |
| title_short | Antibacterial Therapy in Adults with COVID-19 |
| title_sort | antibacterial therapy in adults with covid 19 |
| topic | COVID-19 antimicrobial use multicentre point-prevalence study Influenza co-infection secondary infections aspergillosis ivermectin randomized-controlled trial prevention treatment SARS-CoV-2 antiviral antibiotic azithromycin remdesivir macrolides virus coronavirus immunolides antivirus pandemics procalcitonin SARS virus community-acquired infections emergency service hospital pneumonia viral community-acquired pneumonia Mid-regional Pro-adrenomedullin ARDS biomarker prognosis superinfection bacterial co-infection bacterial superinfection antibiotic stewardship AMR antibiotics cephalosporin secondary infection variant of concern interleukin-6 receptor antagonist early administration mortality rates thema EDItEUR::M Medicine and Nursing thema EDItEUR::M Medicine and Nursing::MJ Clinical and internal medicine |
| topic_facet | COVID-19 antimicrobial use multicentre point-prevalence study Influenza co-infection secondary infections aspergillosis ivermectin randomized-controlled trial prevention treatment SARS-CoV-2 antiviral antibiotic azithromycin remdesivir macrolides virus coronavirus immunolides antivirus pandemics procalcitonin SARS virus community-acquired infections emergency service hospital pneumonia viral community-acquired pneumonia Mid-regional Pro-adrenomedullin ARDS biomarker prognosis superinfection bacterial co-infection bacterial superinfection antibiotic stewardship AMR antibiotics cephalosporin secondary infection variant of concern interleukin-6 receptor antagonist early administration mortality rates thema EDItEUR::M Medicine and Nursing thema EDItEUR::M Medicine and Nursing::MJ Clinical and internal medicine |
| url | ONIX_20230405_9783036568133_80 |